secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2022-05-25T23:59:59+00:00
Accession:  0000950142-22-001710
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma CFO Ira Strassberg and General Counsel Daigneault resign, effective July 18
--------------------------------------------------------------------------------

- CFO Ira Strassberg and Chief Corporate Officer/GC Alessandra Daigneault resigned May 19, effective July 18, 2022.
- Daigneault leaves to pursue other interests; Deputy General Counsel Michael Kunz expected to assume GC and Secretary role.
- Board to conduct search for successor CFO; Strassberg remains until departure.
- Departures come about one year after NRx's merger with Big Rock Partners in May 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222001710/0000950142-22-001710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222001710/eh220256001_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-001710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer